ID   USPC-ARK-3
AC   CVCL_IV74
SY   USPC ARK-3; USPC-ARK3; ARK3
DR   Wikidata; Q54991972
RX   PubMed=19920829;
RX   PubMed=21246534;
RX   PubMed=23891627;
RX   PubMed=25268372;
CC   Population: African American.
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
DI   NCIt; C27838; Endometrial serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   59Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 29-06-23; Version: 5
//
RX   PubMed=21246534; DOI=10.1002/cncr.25891; PMCID=PMC3128671;
RA   Varughese, Joyce
RA   Cocco, Emiliano
RA   Bellone, Stefania
RA   de Leon, Maria
RA   Bellone, Marta
RA   Todeschini, Paola
RA   Schwartz, Peter E.
RA   Rutherford, Thomas J.
RA   Pecorelli, Sergio
RA   Santin, Alessandro D.
RT   "Uterine serous papillary carcinomas overexpress human
RT   trophoblast-cell-surface marker (Trop-2) and are highly sensitive to
RT   immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal
RT   antibody.";
RL   Cancer 117:3163-3172(2011).
//
RX   PubMed=25268372; DOI=10.1038/bjc.2014.519; PMCID=PMC4453741;
RA   Schwab, Carlton L.
RA   Bellone, Stefania
RA   English, Diana P.
RA   Roque, Dana Marie
RA   Lopez, Salvatore
RA   Cocco, Emiliano
RA   Nicoletti, Roberta
RA   Bortolomai, Ileana
RA   Bonazzoli, Elena
RA   Ratner, Elena
RA   Silasi, Dan-Arin
RA   Azodi, Masoud
RA   Schwartz, Peter E.
RA   Rutherford, Thomas J.
RA   Santin, Alessandro D.
RT   "Afatinib demonstrates remarkable activity against HER2-amplified
RT   uterine serous endometrial cancer in vitro and in vivo.";
RL   Br. J. Cancer 111:1750-1756(2014).
//
RX   PubMed=23891627; DOI=10.1016/j.ajog.2013.07.020;
RA   English, Diana P.
RA   Bellone, Stefania
RA   Cocco, Emiliano
RA   Bortolomai, Ileana
RA   Pecorelli, Sergio
RA   Lopez, Salvatore
RA   Silasi, Dan-Arin
RA   Schwartz, Peter E.
RA   Rutherford, Thomas J.
RA   Santin, Alessandro D.
RT   "Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications
RT   determine the sensitivity of uterine serous carcinoma cell lines to
RT   GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase
RT   (TORC1/2).";
RL   Am. J. Obstet. Gynecol. 209:465.e1-465.e9(2013).
//
RX   PubMed=19920829; DOI=10.1038/sj.bjc.6605448; PMCID=PMC2813756;
RA   El-Sahwi, Karim S.
RA   Bellone, Stefania
RA   Cocco, Emiliano
RA   Cargnelutti, Marilisa
RA   Casagrande, Francesca
RA   Bellone, Marta
RA   Abu-Khalaf, Maysa
RA   Buza, Natalia
RA   Tavassoli, Fattaneh A.
RA   Hui, Pei
RA   Silasi, Dan-Arin
RA   Azodi, Masoud
RA   Schwartz, Peter E.
RA   Rutherford, Thomas J.
RA   Pecorelli, Sergio
RA   Santin, Alessandro D.
RT   "In vitro activity of pertuzumab in combination with trastuzumab in
RT   uterine serous papillary adenocarcinoma.";
RL   Br. J. Cancer 102:134-143(2010).
//